Author

David Santamarı́a

Consejo Superior de Investigaciones CientíficasORCID 0000-0002-4711-3569Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Adrián Varela-VázqueziD· 1 shared Alberto MartíniD· 1 shared Alberto VillanuevaiD· 1 shared Alexander Carneiro-Figueira· 1 shared Amanda Guitián‐CaamañoiD· 1 shared Antoni RiéraiD· 1 shared Anxo VidaliD· 1 shared Bárbara M. G. BarbosaiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrián Varela-VázquezORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeted KRAS(G12V) degradation elicits efficient and durable lung adenocarcinoma regression in vivo

Alberto Martín, Inés María García-Pérez, Sonia San José, Pep Rojo, Carlos Riego‐Mejías, Cristina Teodósio, Bárbara M. G. Barbosa, Carolina Sánchez, Ignasi Folch-I-Casanovas, María Antonia Odena, Sònia Jarió, Sara Hijazo‐Pechero, Silvia M. Rodríguez-López, Rodrigo Entrialgo‐Cadierno, Marie‐Julie Nokin, , Cristina Mayor‐Ruiz

This study shows that targeted KRAS(G12V) degradation causes durable lung adenocarcinoma regression in mice, with tumor relapse linked to proteolysis machinery dysregulation.

Cancer Research · May 27, 2026Peer-reviewedCancer Biology

Cx43 Enhances Response to BRAF/MEK Inhibitors by Reducing DNA Repair Capacity

Adrián Varela-Vázquez, Amanda Guitián‐Caamaño, Paula Carpintero-Fernández, Alexander Carneiro-Figueira, Vanesa Álvarez, Marta Varela-Eirín, Teresa Calleja-Chuclá, Susana B. Bravo, Anxo Vidal, Juan Sendón-Lago, Marina Rodríguez-Candela Mateos, José Ramón Caeiro, Victoria Sanz‐Moreno, Trond Aasen, Miguel G. Blanco, , María D. Mayán

This study shows that Cx43 enhances the effectiveness of BRAF/MEKi by reducing DNA repair, leading to increased DNA damage and cellular senescence, and proposes a novel therapeutic approach using sEVs.

Nature Communications · Jul 4, 2025Peer-reviewedCancer Biology